- Conditions
- Marburg Virus Disease
- Interventions
- cAd3-Marburg Vaccine, Placebo
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 143
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus, Filovirus
- Interventions
- VRC-EBOADV018-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Interventions
- Trivirus-Specific CTLs
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Adenovirus
- Interventions
- Not listed
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 17 Years to 50 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- HIV
- Interventions
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Cancer, Epithelial Tumor
- Interventions
- NG-350A
- Biological
- Lead sponsor
- Akamis Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Aurora, Colorado • New York, New York + 2 more
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Ad26.ZEBOV, MVA-BN-Filo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 0 Years to 71 Years
- Enrollment
- 677 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Norovirus Infections
- Interventions
- VXA-G1.1-NN
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy Volunteer
- Interventions
- Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Conjunctivitis
- Interventions
- RPS Adeno Detector IV
- Device
- Lead sponsor
- Rapid Pathogen Screening
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Bradenton, Florida • Miami, Florida • Springfield, Missouri + 5 more
- Conditions
- Influenza A Subtype H5N1 Infection
- Interventions
- Pandemic Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 19 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Wounds and Injuries, Diabetes, Diabetic Foot Ulcers, Foot Wounds
- Interventions
- GAM501
- Genetic
- Lead sponsor
- Tissue Repair Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • San Diego, California
- Conditions
- HIV Infections
- Interventions
- VRC-HIVADV014-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 3
- States / cities
- San Francisco, California • Nashville, Tennessee • Seattle, Washington
- Conditions
- Pancreatic Cancer
- Interventions
- delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel, atezolizumab
- Genetic · Drug · Biological
- Lead sponsor
- Lokon Pharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Plasmodium Falciparum
- Interventions
- NMRC-M3V-Ad-PfCA, NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Hyponatremia, SIADH
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Polderman, Kees, H., MD, PhD
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Interventions
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Biological · Drug
- Lead sponsor
- TILT Biotherapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • New York, New York
- Conditions
- Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
- Interventions
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25,236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
- Conditions
- HIV Infections
- Interventions
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 2,504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- HIV Infections
- Interventions
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Interventions
- oncolytic adenovirus expressing GMCSF
- Biological
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
- Interventions
- artus Influenza A/B RT-PCR Test
- Device
- Lead sponsor
- QIAGEN Gaithersburg, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma Multiforme, Astrocytoma, Grade III, Astrocytoma, Grade IV, Brain Cancer
- Interventions
- Neural stem cells loaded with an oncolytic adenovirus
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Duarte, California • Chicago, Illinois